Novartis: highlights drugs pipeline to investors

(CercleFinance.com) - Novartis is holding today an R&D and investor update in London, providing insights into its late-stage pipeline of medicines.


The Swiss drugmaker said 26 potential blockbusters are now in confirmatory development, with 13 projects in clinical development across cell, gene and radio therapies.

In all, 60 major submissions are planned from 2019 to 2021, the company said.

The gene therapy AVXS101 in spinal muscular atrophy Type 1 is expected to receive regulatory approvals in US, Europe and Japan in the first half of 2019.

Last Friday, Novartis also said that its biosimilar unit Sandoz has decided to pursue its submission for a generic version of Roche's Mabthera in the US.

The decision follows a request by the US Food and Drug Administration (FDA) for additional information to complement the submission, it said.

Novartis shares are currently up 0.3% at 88 Swiss francs in Zurich.

Copyright (c) 2018 CercleFinance.com. All rights reserved.